Earnings Reports

Found 86,015 articles

• Immunovia Publishes Interim Report for January-March 2023

  5/23/2023

  Net sales amounted to kSEK 520 (182) divided by sales of tests kSEK 379 (122) and royalties kSEK 141(60).

• IceCure Medical Reports First Quarter 2023 Financial & Operational Results

  5/22/2023

  IceCure Medical Ltd. today reported financial results as of and for the three months ended March 31, 2023 as well as operational and recent corporate developments.

• Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023

  5/22/2023

  Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fiscal fourth quarter and fiscal year ended March 31, 2023.

• Nordson Corporation Reports Second Quarter Fiscal 2023 Results and Updates Annual Guidance

  5/22/2023

  Nordson Corporation reported results for the fiscal second quarter ended April 30, 2023. Sales were $650 million, a 2% increase compared to the prior year’s second quarter sales of $635 million.

• Kelyniam Global Releases Q1 Financials, Announces Licensing Agreement with Bioplate for Osteopore Products

  5/22/2023

  Kelyniam Global, a leading maker of custom cranial implants, announced results for its quarter ended March 31, 2023.

• Lifecore Biomedical Sets Third Quarter 2023 Earnings Conference Call for June 1, 2023 at 7:30 a.m. CT

  5/22/2023

  Lifecore Biomedical, Inc., a fully integrated contract development and manufacturing organization, announced that it will host a conference call to discuss fiscal 2023 third quarter financial results.

• T2 Biosystems Reschedules First Quarter 2023 Financial Results Reporting to May 23, 2023

  5/22/2023

  T2 Biosystems, Inc. announced today it has rescheduled its first quarter 2023 financial results reporting to before market open on Tuesday, May 23, 2023.

• Abeona Therapeutics Announces Date Change for First Quarter 2023 Portfolio Update Conference Call to May 24, 2023

  5/22/2023

  Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has changed the date of its previously announced First Quarter 2023 Portfolio Update conference call and webcast to Wednesday, May 24, 2023, at 8:30 a.m. ET. The call was previously scheduled for Tuesday, May 23, 2023, at 8:30 a.m. ET.

• Nanox Announces First Quarter of 2023 Financial Results and Provides Business Update

  5/22/2023

  NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced results for the first quarter ended March 31, 2023 and provided a business update.

• Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2023 and Recent Corporate Progress

  5/22/2023

  Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today reported its three months ended March 31, 2023 financial results and highlighted recent corporate progress.

• Journey Medical Corporation Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

  5/22/2023

  Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”) today announced financial results and recent corporate highlights for the first quarter ended March 31, 2023.

• Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates

  5/22/2023

  Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today reported first quarter financial results and provided an update on its business.

• Catalent to Hold Business Update Call Related to Delay of Third Quarter 2023 Results and Receives NYSE Notice Regarding Late Form 10-Q Filing

  5/19/2023

  Catalent to Hold Business Update Call Related to Delay of Third Quarter 2023 Results and Receives NYSE Notice Regarding Late Form 10-Q Filing.

• Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 22, 2023

  5/19/2023

  Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM) today announced the Company will release its first quarter 2023 financial results after the U.S. financial markets close on Monday, May 22, 2023.

• NanoVibronix Issues Letter to Shareholders - May 18, 2023

  5/18/2023

  NanoVibronix, Inc. today issued a letter to shareholders from its Chief Executive Officer, Brian Murphy, providing a review of the first quarter 2023 and recent business developments.

• Legend Biotech Reports First Quarter 2023 Results and Recent Highlights

  5/18/2023

  Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today reported its first quarter 2023 unaudited financial results.

• Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Update

  5/18/2023

  Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and year ended March 31, 2023 and provided a business update.

• MedAvail to Report First Quarter 2023 Financial Results on May 18

  5/18/2023

  MedAvail Holdings, Inc. today announced that the Company will announce financial results for the first quarter ended March 31, 2023, on Thursday, May 18th, after the close of the financial markets.

• Kane Biotech to Release First Quarter 2023 Financial Results on May 25, 2023 – Conference Call to Follow

  5/18/2023

  Kane Biotech Inc., a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce its first quarter 2023 financial results after market close on Thursday, May 25, 2023.

• Evogene Reports First Quarter 2023 Financial Results

  5/18/2023

  Evogene Ltd. today announced its financial results for the first quarter period ending March 31, 2023.